Dataset from A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Maintenance of Clinical Remission in Subjects With Crohn's Disease
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/00002950
下载链接
链接失效反馈官方服务：
资源简介：
The objectives were: (1) To demonstrate the efficacy of adalimumab in the maintenance of clinical remission up to 56 weeks in participants with Crohn's disease who participated in NCT00055523; (2) To delineate the safety of adalimumab when administered to participants with Crohn's disease up to 56 weeks.
创建时间：
2025-07-24
